Clinical trials: PTE - Pulmonary Thromboembolism
Pulmonary Embolism, Pulmonary Thromboembolism
Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
Recombinant streptokinase (r-SK) is an effective thrombolytic agent developed with gene engineering. Its characteristics of high output and low production cost make it affordable in treating acute myocardial infarction (AMI) in…
- Trial name
- RESUPEC (NCT00968929)
- Testing
- Recombinant Streptokinase, Urokinase
- Where
- 8 sites in China
- Volunteers
- 83 people
- Sponsor
- Beijing Chao Yang Hospital